# Semax (Russian Nootropic Peptide)

**Last Updated:** December 4, 2025
**OCEBM Evidence Level:** 3-4 (Russian regulatory approval + clinical data)
**Risk Profile:** LOW
**Regulatory Status:** Approved in Russia since 2011

---

## What Is This?

Semax is a Russian nootropic peptide approved for stroke recovery and cognitive enhancement since 2011. It works by increasing BDNF (brain-derived neurotrophic factor) — the protein that helps neurons grow and form new connections. Users report improved focus, mental clarity, and motivation within 30 minutes of nasal administration. Think of it as Selank's energizing counterpart: while Selank calms, Semax stimulates. Most popular as a 2-week cycle for studying, demanding projects, or depression.

---

## Categories

`Cognitive` · `Mood & Stress`

---

## Glossary

| Term | Meaning |
|------|---------|
| OCEBM | Oxford Centre for Evidence-Based Medicine — rates evidence quality |
| BDNF | Brain-Derived Neurotrophic Factor — protein that supports neuron growth and plasticity |
| ACTH | Adrenocorticotropic Hormone — Semax is derived from ACTH fragment 4-10 |
| MC3/MC4 | Melanocortin receptors 3 and 4 — involved in energy, mood, and cognition |
| NGF | Nerve Growth Factor — supports nerve cell survival |
| Intranasal | Administered through the nose for direct CNS access |
| N-Acetyl Semax | Modified version with enhanced potency (~2x) |
| NASA | N-Acetyl Semax Amidate — most potent form (~3-4x) |
| Racetams | Class of nootropic drugs that Semax can stack with |

---

## Key Specifications

| Property | Value |
|----------|-------|
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro (ACTH 4-10 + Pro-Gly-Pro) |
| Molecular Weight | 813.93 g/mol |
| Half-life | ~30-60 minutes (effects persist longer) |
| Administration | Intranasal |
| Russian Indications | Stroke, cognitive enhancement, optic nerve atrophy |
| Developer | Institute of Molecular Genetics, Russian Academy of Sciences |

---

## Clinical Evidence

The clinical evidence for Semax originates primarily from Russian research institutions and forms the basis of its regulatory approval in that country. While Western peer-reviewed literature remains limited, the existing studies demonstrate consistent effects across both clinical populations and healthy volunteers.

### Stroke Recovery and Neuroprotection

The most robust clinical data comes from stroke rehabilitation studies. A trial involving 110 stroke patients administered Semax in two courses: 6000mcg daily for 10 days, separated by a 20-day interval. Plasma BDNF levels increased measurably during treatment, and neurological function improved compared to control groups receiving standard care alone. This evidence proved sufficient for Russian regulatory approval of Semax as a stroke recovery agent — a remarkable achievement given the limited pharmacological options for acute neurological injury.

The therapeutic effect in stroke appears to stem from Semax's ability to upregulate neurotrophic factors during the critical window when neural tissue is attempting recovery. While damaged neurons cannot regenerate, the surrounding tissue can reorganize and compensate. Semax appears to facilitate this neuroplastic response.

### Cognitive Enhancement in Healthy Individuals

Beyond clinical populations, Semax demonstrates measurable cognitive effects in healthy volunteers. Studies using doses ranging from 250 to 1000mcg per administration (approximately 3-15mcg/kg body weight) showed improvements in attention and short-term memory tasks. Electroencephalography revealed changes in brain electrical activity similar to other established neuroprotective agents, suggesting genuine neurophysiological modulation rather than placebo effect.

Safety studies have documented tolerance up to 12mg daily for 10 consecutive days without serious adverse effects. This dose is substantially higher than typical nootropic protocols, providing some reassurance about the compound's therapeutic window.

### Evidence Limitations

The primary weakness is geographic concentration. Most published studies originate from Russian institutions, with limited independent replication in Western research settings. This doesn't invalidate the findings — the methodology appears sound — but it does limit confidence in generalizability. Regulatory approval in a major country with an established pharmaceutical infrastructure does carry weight, but it's not equivalent to FDA or EMA approval standards.

---

## Mechanism of Action

Semax operates through multiple neurochemical pathways, with its effects extending beyond simple receptor modulation into gene-level regulation of neurotrophic factors. The compound's structure — derived from ACTH fragments 4-10 with an additional Pro-Gly-Pro tripeptide tail — gives it access to melanocortin receptors while providing stability against enzymatic degradation.

The primary mechanism centers on BDNF (brain-derived neurotrophic factor) upregulation. Semax increases BDNF protein levels by 1.4 to 1.6-fold, but the transcriptional effect is more dramatic: BDNF exon III mRNA increases 3-fold. This suggests Semax doesn't merely preserve existing BDNF but actively drives new synthesis. BDNF is critical for synaptic plasticity, long-term potentiation, and neuronal survival — the cellular foundation of learning, memory, and recovery from injury.

The dopaminergic system shows clear enhancement, though the precise receptor mechanisms remain incompletely characterized. Users consistently report improved motivation, drive, and reward sensitivity — hallmarks of dopaminergic modulation. The serotonergic system also responds, contributing to mood stabilization and stress resilience.

Semax's structural heritage as an ACTH derivative grants it melanocortin receptor activity, particularly at MC3 and MC4. These receptors influence energy balance, cognitive function, and mood — a mechanistic explanation for Semax's activating, energizing character compared to Selank's calming profile.

Nerve growth factor (NGF) levels also increase, supporting peripheral and central nervous system maintenance. This multi-pathway approach may explain why Semax appears effective across diverse contexts — cognitive enhancement, mood support, and neuroprotection — rather than targeting a single narrow indication.

---

## Forms

| Form | Modification | Relative Potency |
|------|--------------|------------------|
| Semax 0.1% | Base peptide | 1x |
| Semax 1% | Higher concentration | 1x (higher dose) |
| N-Acetyl Semax | Acetylation | ~2x |
| N-Acetyl Semax Amidate (NASA) | Acetyl + Amide | ~3-4x |

---

## Use Cases by Goal

### Cognitive Enhancement and Nootropic Application

The nootropic use case leverages Semax's dual action on BDNF and dopaminergic systems. BDNF upregulation supports the physical substrate of cognition — dendritic branching, synaptic density, long-term potentiation. Dopaminergic enhancement provides the functional component — motivation, reward salience, working memory capacity, and sustained attention.

The typical protocol involves 200-400mcg administered intranasally 2-3 times daily, structured as 10-14 day courses with breaks of similar duration. This cycling approach reflects Russian clinical practice and aims to prevent potential receptor downregulation or tolerance, though formal tolerance studies are limited.

Timing matters significantly. Semax is activating, not sedating. Morning and early afternoon administration works best; late-day dosing may interfere with sleep in sensitive individuals. Effects manifest within 30 minutes — users describe improved focus, mental clarity, and elevated motivation baseline. The experience differs from caffeine's peripheral stimulation; Semax provides cognitive activation without jitteriness or cardiovascular effects.

### Stroke Recovery and Neuroprotection

This represents Semax's approved medical indication in Russia. The rationale is straightforward: stroke creates a window where surviving neural tissue must compensate for lost function, and BDNF is the primary signal driving neuroplastic reorganization. By upregulating BDNF during this critical period, Semax may accelerate functional recovery.

The clinical protocol is aggressive: 6000mcg daily for 10 days, repeated after a 20-day interval. This dosing is substantially higher than nootropic applications and should be viewed as a medical intervention rather than cognitive optimization. The n=110 clinical trial demonstrated increased plasma BDNF levels and improved neurological function scores compared to standard rehabilitation alone.

User reports describe faster-than-expected cognitive recovery post-stroke, though these anecdotal accounts cannot substitute for controlled trials. The mechanism is plausible, the dosing is established, and the approval suggests acceptable risk-benefit in this high-stakes context.

### Depression and Motivation Deficits

Depression often involves dopaminergic and serotonergic dysfunction, particularly in cases characterized by anhedonia, low energy, and motivation deficits. Semax's modulation of both systems positions it as a potential intervention for this specific depression subtype.

Protocols typically involve 400-600mcg administered 2-3 times daily for 2-4 weeks. Users report mood elevation and restored drive — the subjective sense of being able to initiate and sustain goal-directed behavior. Descriptions include "helped break through depression fog" and "motivation baseline elevated."

This is not a replacement for established antidepressants, particularly in severe or suicidal depression. But for mild-to-moderate cases, especially those with prominent motivational symptoms, Semax represents a mechanistically distinct option with a favorable side effect profile compared to traditional antidepressants.

### Learning and Memory Enhancement

The BDNF connection to neuroplasticity makes Semax particularly relevant for learning contexts. BDNF supports memory consolidation — the process by which short-term experiences become stable long-term memories. Language learning, skill acquisition, and academic study all depend on this process.

The protocol is flexible: 200-400mcg administered 30 minutes before studying or practice sessions, either as-needed or during intensive learning blocks. Users report improved information retention and faster skill acquisition, particularly for language learning where pattern recognition and procedural memory are critical.

The effect is not limitless. Semax doesn't create photographic memory or eliminate the need for practice. But it appears to optimize the neurobiological conditions under which learning occurs, making the same effort more productive.

### Athletic Performance and Training

The athletic application leverages Semax's central nervous system effects — enhanced focus, motivation, and mind-muscle connection. While Semax isn't anabolic or directly performance-enhancing in a physiological sense, the quality of training execution matters enormously for adaptation.

Protocols involve 400-600mcg administered 30-60 minutes before training. Users describe improved workout focus and stronger mind-muscle connection — the ability to consciously recruit and control specific muscle groups during complex movements. This is particularly relevant for technical athletic skills and strength training where motor control precision drives progress.

### Combination with Selank: The Balanced Stack

Semax and Selank represent complementary neurochemical profiles. Semax stimulates (dopaminergic, activating, focus-enhancing) while Selank calms (GABAergic, anxiolytic, stress-reducing). The combination addresses a common problem: cognitive demands often trigger anxiety, and anxiety management often impairs cognition.

The typical protocol pairs equal doses — 400mcg of each in the morning. Users describe "calm productivity" and "focused but not wired" — the ability to sustain cognitive effort without mounting tension or anxiety. This stack is particularly popular in high-pressure contexts: examinations, presentations, intense work periods.

The mechanistic logic is sound. Dopaminergic activation without GABAergic balance can produce overstimulation and anxiety. GABAergic calming without dopaminergic drive can produce relaxation without productivity. The combination attempts to occupy the optimal zone between these extremes.

---

## Timing and Administration

### Intranasal (Primary Route)

1. Clear nasal passages
2. Tilt head slightly back
3. Administer drops/spray
4. Sniff gently
5. Alternate nostrils for divided doses

### Why Intranasal

- Bypasses digestive degradation
- Direct CNS access via olfactory pathway
- Rapid onset (15-30 min)

### Timing Strategies

| Goal | Best Time |
|------|-----------|
| Cognitive work | Morning/early afternoon |
| Learning | 30 min before task |
| Training | Pre-workout |
| Depression | Morning + early PM |

**Avoid:** Late afternoon/evening (may interfere with sleep).

---

## User Experience Timeline

| Timeframe | Reported Effects |
|-----------|------------------|
| 15-30 min | Onset of focus/clarity |
| Hours 1-4 | Peak cognitive enhancement |
| Days 3-7 | Cumulative effects build |
| Week 2 | Full nootropic benefit |
| Post-cycle | Effects persist briefly |

---

## Dosing Summary

| Protocol | Dose | Frequency |
|----------|------|-----------|
| Nootropic | 200-600mcg | 2-3x daily intranasal |
| Neuroprotection | 500-1000mcg | 2-3x daily |
| Pre-task | 200-400mcg | As needed |
| With Selank | 400mcg each | Morning |

**Russian Protocol:** 10-14 day courses with break of similar duration.

### Forms Available

| Form | Relative Potency |
|------|------------------|
| Semax 0.1% | 1x |
| Semax 1% | Higher dose |
| N-Acetyl Semax | ~2x |
| N-Acetyl Semax Amidate (NASA) | ~3-4x |

---

## Risk Assessment

Semax's safety profile benefits from over a decade of clinical use in Russia, where it maintains regulatory approval for medical indications. This represents a substantially different risk picture than compounds with purely anecdotal or gray-market histories.

Studies specifically examining abuse potential found no evidence of addiction, physical dependence, or tolerance development during 14-day administration courses. No withdrawal symptoms emerge upon cessation — users can stop without tapering or rebound effects. This distinguishes Semax from many psychoactive substances and makes it suitable for intermittent use.

Serious adverse effects at standard doses are not reported in the literature. The common effects are predictable consequences of the mechanism and administration route: mild stimulation (expected from dopaminergic modulation), nasal dryness (intranasal administration), and occasional transient headaches, particularly at higher doses or in new users.

The stimulating character does create specific risks. Late afternoon or evening dosing can interfere with sleep, particularly in individuals prone to insomnia or anxiety. This is a timing problem, not a fundamental safety issue, but it requires attention to administration schedule.

The standard cycling protocol — 10 to 14 day courses with breaks of equal or longer duration — reflects Russian clinical practice rather than demonstrated necessity. Continuous use beyond this timeframe hasn't been formally studied in long-term trials. Given Semax's favorable acute safety profile, the primary concern with extended use would be potential receptor downregulation or tolerance, though neither has been documented. The cycling approach represents conservative practice in the absence of long-term data.

### Risk Mitigation

Two rules matter most:

**Timing discipline:** Avoid late dosing in anxiety-prone or insomnia-prone individuals. Morning and early afternoon administration allows effects to peak and recede before evening, minimizing sleep interference.

**Cycling practice:** Structure use as 10-14 day courses with breaks of equal or longer duration. Avoid continuous month-over-month administration given the absence of long-term safety studies.

---

## Synergies and Stacking Rationale

### Semax with Selank: The Balanced Cognitive Stack

This represents the most popular and mechanistically coherent Semax combination. Semax provides dopaminergic stimulation, focus enhancement, and motivation drive. Selank provides GABAergic calming and anxiety reduction without sedation. The combination addresses the fundamental tension between cognitive activation and emotional regulation.

High-demand cognitive work often generates anxiety. Anxiety management often impairs cognitive performance. The Semax-Selank stack attempts to solve both simultaneously: maintain cognitive activation while preventing anxiety escalation. Users describe "focused but not wired" states and "calm productivity" — the ability to sustain intense mental effort without mounting tension.

The typical protocol pairs equal doses, usually 400mcg of each compound administered together in the morning. Both are intranasal, making co-administration straightforward. The effects complement rather than interfere — the calming doesn't eliminate the focus, and the stimulation doesn't override the anxiolysis.

### Semax with Racetams: Synergistic Cognitive Enhancement

Racetams (piracetam, aniracetam, phenylpiracetam) modulate acetylcholine and glutamate systems, with effects on neuroplasticity and cognitive function. Semax's BDNF upregulation and dopaminergic enhancement operate through different pathways, suggesting potential synergy rather than redundancy.

The mechanistic logic: BDNF creates structural capacity for enhanced cognition (more dendritic spines, stronger synapses), while racetams and dopamine modulate the functional utilization of that capacity (neurotransmitter efficiency, working memory, attention). Building the substrate while optimizing its use.

Anecdotal reports suggest enhanced cognitive effects beyond either compound alone, though formal combination studies don't exist. Users typically maintain standard Semax dosing (200-400mcg 2-3x daily) while adding racetam doses per those compounds' protocols. The combination is popular in nootropic-focused communities but lacks clinical validation.

---

## Limitations

1. **English-language studies limited** - Most evidence in Russian
2. **Not approved in Western countries**
3. **No large-scale RCTs** published internationally
4. **Quality varies** by source

---

## References

1. Gusev EI, et al. Semax in prevention and treatment of brain damage in acute stroke. Zh Nevrol Psikhiatr. 2005.
2. Eremin KO, et al. Semax activates dopaminergic and serotoninergic systems. Neurochem Res. 2005.
3. Dolotov OV, et al. Semax regulates BDNF and trkB expression in hippocampus. Brain Res. 2006.
4. Alzheimer's Drug Discovery Foundation: Semax Cognitive Vitality Report.
5. Genome-wide transcriptional analysis of Semax in rat brain ischemia. PMC3987924.
